References
- Goldberg P, Bozzo J, Thomas P, . ‘Glucometrics’: Assessing the quality of inpatient glucose management. Diabetes Technol Ther. 2006;8:560–9.
- Badawi O, Yeung S, Rosenfeld B. Evaluation of glycemic control metrics for intensive care unit populations. Am J Med Qual. 2009;XX:1–10.
- Vogelzang M, van der Horst I, Nijsten M. Hyperglycaemic index as a tool to assess glucose control: A retrospective study. Crit Care 2004;8:122–7.
- Hayden M, Tyagi S. Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovasc Diabetol. 2003;2:2.
- Ancey C, Corbi P, Froger J, Delwail A, Wijdenes J, Gascan H, . Secretion ofIL-6, IL-11 and LIF by human cardiomyocytes in primary culture. Cytokine 2002;18:199–205.
- Saadeddin SM, Habbab MA, Ferns GA. Markers of inflammation and coronary artery disease. Med Sci Monit. 2002;8:RA5–RA12.
- Libby P, Crea F. Clinical implications of inflammation for cardiovascular primary prevention. Eur Heart J. 2010;31:777783.
- Bassuk Sh, Rifai N, Ridker P. High sensitive C-reactive protein: Clinical importance Curr Probl Cardiol. 2004;29:439–93.
- Dungan KM, Braithwaite SS, Preiser J-C. Stress hyperglycaemia. Lancet 2009;373:1798–807.
- Zacho J, Hansen A, Nordestgaard B. C-reactive protein and all-cause mortality—the Copenhagen city heart study. Eur Heart J. 2010;31:1624–32.
- Chazova T, Masenko V, Zykov K, Golitsyna TIu. The role of inflammation factors in development of ACS in patients with type 2 diabetes mellitus and impaired glucose tolerance. Teрапевтический архив. 2007;6:60–4.
- Duarte EL, Pellanda, V. Portal. Inflammatory, lipid, and metabolic profile in acute ischemic syndrome. Correlation with hospital and posthospital events. Arq Bras Cardiol. 2005;84:1229.
- Roubille F, Samri A, Cornillet L, Sportouch-Dukhan C, Davy JM, Raczka F, . Routinely-feasible multiple biomarkers score to predict prognosis after revascularized STEMI. Eur J Int Med. 2010;21:131–6.